Clene (CLNN) Expected to Announce Earnings on Monday

Clene (NASDAQ:CLNN) is projected to release its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Clene to post earnings of ($0.74) per share and revenue of $0.0260 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 20, 2026 at 9:30 AM ET.

Clene (NASDAQ:CLNN) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.14). The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.03 million. On average, analysts expect Clene to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Clene Stock Down 9.4%

Shares of NASDAQ:CLNN opened at $5.32 on Friday. The business has a fifty day simple moving average of $4.97 and a 200 day simple moving average of $6.72. The firm has a market cap of $62.67 million, a P/E ratio of -2.05 and a beta of 0.62. Clene has a 12-month low of $2.28 and a 12-month high of $13.50.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CLNN. D. Boral Capital reiterated a “buy” rating and issued a $23.00 target price on shares of Clene in a report on Thursday, March 12th. Benchmark reiterated a “buy” rating on shares of Clene in a research note on Thursday, December 4th. UBS Group reiterated a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a research note on Friday, January 9th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $48.00 price target on shares of Clene in a research note on Friday, March 13th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.60.

Insider Buying and Selling

In related news, major shareholder Chidozie Ugwumba sold 32,705 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $5.50, for a total value of $179,877.50. Following the completion of the sale, the insider directly owned 708,587 shares of the company’s stock, valued at approximately $3,897,228.50. This represents a 4.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director David J. Matlin acquired 33,333 shares of the business’s stock in a transaction on Tuesday, January 13th. The shares were purchased at an average cost of $6.50 per share, for a total transaction of $216,664.50. Following the completion of the acquisition, the director directly owned 477,824 shares in the company, valued at approximately $3,105,856. The trade was a 7.50% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders sold 261,862 shares of company stock worth $1,382,424 in the last 90 days. Corporate insiders own 35.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in Clene during the second quarter valued at $47,000. State Street Corp lifted its position in shares of Clene by 138.4% during the 4th quarter. State Street Corp now owns 29,801 shares of the company’s stock valued at $175,000 after buying an additional 17,300 shares during the last quarter. PEAK6 LLC bought a new position in shares of Clene during the 4th quarter worth $294,000. Geode Capital Management LLC grew its stake in shares of Clene by 8.0% during the 4th quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock worth $482,000 after acquiring an additional 6,090 shares during the period. Finally, Ensign Peak Advisors Inc increased its holdings in Clene by 668.6% in the 4th quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock worth $671,000 after acquiring an additional 99,481 shares during the last quarter. Institutional investors own 23.28% of the company’s stock.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).